Oslo, Norway ,March 6, 2024 -EXACT Therapeutics AS (Euronext Growth: EXTX), a clinical stage precision health company utilizing Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today announced that it will be presenting a poster on the ACTIVATE trial in patients with liver metastases of colorectal cancer origin at the upcoming 2024American Association for Cancer Research (AACR) Annual Meeting, taking placeApril 5-10, 2024 , inSan Diego, California . Dr.Amir Snapir , Chief Medical Officer of EXACT-Tx and Dr.Udai Banerji , the principal investigator of the ACTIVATE trial will present the poster. Dr.Amir Snapir comments: "We are excited to be at AACR to present details from the promising ACTIVATE trial and supporting preclinical data. We are looking very much forward to meeting other industry leaders and researchers here at AACR's annual meeting." Details of the poster presentation are as follows: Abstract #: 6221 Title: First-in-Human Study of Acoustic Cluster Therapy (ACT®) consisting of PS101 combined with Chemotherapy and insonation in Patients with Liver Metastases of Colorectal Cancer Origin Session date, time and location:April 9 at1:30 p.m. - 5:00 p.m. in Poster Section 36 The poster will be made available in the Research Papers section of the Company's website: https://exact-tx.com/publications-1-1 in parallel with the Session. For more information, please contact: Per Walday CEO EXACT Therapeutics Email: per.walday@exact-tx.com About EXACT-Tx: EXACT-Tx is a clinical-stage Norwegian precision health company developing a technology platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted drug enhancement - with the potential to enable or significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy) and brain diseases. www.exact-tx.com About ACT® o ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent. o ACT® is being tested in the clinic and has released positive interim data. It is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration. o Initial focus of the Company is oncology. The ACT® platform has potential across many therapeutic areas (including CNS, immunotherapy) and product classes. Forward looking statements: This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by this forward-looking statement. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Click here for more information
© Oslo Bors ASA, source